20.500.12556/RUL-155933 Investigating the influence of processing conditions on dissolution and physical stability of solid dispersions with fenofibrate and mesoporous silica The study aimed to enhance the solubility of the poorly water-soluble drug, fenofibrate, by loading it onto mesoporous silica, forming amorphous solid dispersions. Solid dispersions with 30% fenofibrate were prepared using the solvent evaporation method with three solvents (ethyl acetate, acetone, and isopropanol) at different temperatures (40 °C, boiling point temperature). Various characteristics, including solid-state properties, particle morphology, and drug release, were evaluated by different methods and compared to a pure drug and a physical mixture of fenofibrate and silica. Results revealed that higher solvent temperatures facilitated complete amorphization and rapid drug release, with solvent choice having a lesser impact. The optimal conditions for preparation were identified as ethyl acetate at boiling point temperature. Solid dispersions with different fenofibrate amounts (20%, 25%, 35%) were prepared under these conditions. All formulations were fully amorphous, and their dissolution profiles were comparable to the formulation with 30% fenofibrate. Stability assessments after 8 weeks at 40 °C and 75% relative humidity indicated that formulations prepared with ethyl acetate and at 40 °C were physically stable. Interestingly, some formulations showed improved dissolution profiles compared to initial tests. In conclusion, mesoporous silica-based solid dispersions effectively improved fenofibrate dissolution and demonstrated good physical stability if prepared under appropriate conditions. mesoporous silica amorphous solid dispersion solvent evaporation method fenofibrate dissolution physical stability mezoporozni silicijev dioksid amorfna trdna disperzija metoda izhlapevanja topila raztapljanje fenofibrata fizična stabilnost farmacevtske oblike topnost farmacevtska tehnologija true false true Angleški jezik Slovenski jezik Članek v reviji 2024-04-24 12:01:23 2024-04-24 12:01:30 2025-02-03 09:02:43 0000-00-00 00:00:00 2024 0 0 23 str. iss. 5, art. 575 Vol. 16 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 544.351.3:615.45 1999-4923 10.3390/pharmaceutics16050575 193690883 pharmaceutics-16-00575.pdf pharmaceutics-16-00575.pdf 1 6DC998F7D63D3832F026A3BE9718F258 05181ff7d7db48644cbeb2cc32794c6d49b851402a7235173683daee8d31353b fc17d965-0221-11ef-a15b-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=183069 https://www.mdpi.com/1999-4923/16/5/575 1 9fecbb86-0221-11ef-a15b-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=183068 Fakulteta za farmacijo 0 0 0